Latest Breaking News On - Prnewswire acasti pharma inc - Page 1 : comparemela.com

Acasti Pharma Announces 1-for-6 Reverse Stock Split

/PRNewswire/ Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of.

United statesRobert blumPrashant kohliExchange commissionSecurities exchangeComputershare services incLytham partnersPrnewswire acasti pharma incCompany nasdaqAcasti pharma incComputershare servicesOutside north americaOrphan drug designationSubarachnoid hemorrhageSecurities litigation reform actSecurities act

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

STRIVE-ON is the pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety and tolerability profile relative to oral nimodipine in patients hospitalized with aSAH GTX-104 has been.

United statesRobert blumPrashant kohliCompany nasdaqLytham partnersSecurities exchangePrnewswire acasti pharma incDrug administrationExchange commissionAcasti pharma incDrug applicationOral nimodipineSubarachnoid hemorrhageIntensive care unitOrphan drug designationSecurities litigation reform act

Acasti Pharma Reports Fiscal Year 2023 Operational Results

/PRNewswire/ Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of.

United statesPrashant kohliRobert blumLytham partnersSecurities exchangeDrug administrationCompany nasdaqAcasti pharma incPrnewswire acasti pharma incExchange commissionStates foodInvestigational new drugNew drug applicationChief executive officerOrphan drug designationSubarachnoid hemorrhage

Acasti Pharma Inc : Acasti Pharma Reports Fiscal Year 2023 Operational Results

Acasti Pharma Inc : Acasti Pharma Reports Fiscal Year 2023 Operational Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesPrashant kohliRobert blumAcasti pharma incPrnewswire acasti pharma incExchange commissionDrug administrationSecurities exchangeLytham partnersCompany nasdaqStates foodInvestigational new drugNew drug applicationChief executive officerOrphan drug designationSubarachnoid hemorrhage

Acasti Pharma Inc Announces the Resignation of a Director

/PRNewswire/ Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST) a late-stage, specialty pharma company advancing three clinical stage drug.

United statesJean marie john cananRobert blumJan dalvisePrnewswire acasti pharma incBoard of directors the companyAcasti pharma incSecurities exchangeLytham partnersOrphan drug designationSubarachnoid hemorrhagePostherpetic neuralgiaSecurities litigation reform actSecurities actSecurities exchange actAcasti pharma inc